Purdue Pharma, the maker of OxyContin, has been granted an 18-day extension to negotiate a comprehensive settlement for its opioid litigation. This comes after the Supreme Court rejected a previous plan that would have shielded the Sackler family from lawsuits. The extension allows Purdue to modify its approach and potentially salvage parts of the original settlement.
The Supreme Court has rejected a nationwide settlement between Purdue Pharma, the maker of OxyContin, and state and local governments, effectively shielding the Sackler family from lawsuits related to the opioid epidemic. This decision, which came after a 5-4 vote, has significant implications for victims and the fight against opioid addiction.
McKinsey & Co. is being investigated for its role in the opioid epidemic by the US Department of Justice. The probe focuses on whether the firm engaged in a criminal conspiracy while advising Purdue Pharma and other pharmaceutical manufacturers on marketing strategies. The allegations also include healthcare fraud and obstruction of justice. While the investigation is ongoing and no charges have been filed, prosecutors are reviewing a significant amount of documentation.
